Status:
COMPLETED
Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Epidermolysis Bullosa Dystrophica
Eligibility:
All Genders
2+ years
Phase:
PHASE2
Brief Summary
Dystrophic epidermolysis bullosa hereditaria are genodermatosis responsible for formation of cutaneous bullous lesion arising spontaneously or after mechanical trauma. These lesions are due to mutati...
Eligibility Criteria
Inclusion
- known mutation of COL7A1
Exclusion
- tea drinkers
- patient receiving induction treatment,protease inhibitor treatment
- liver failure
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00951964
Start Date
October 1 2010
End Date
July 1 2013
Last Update
May 7 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Department, Bordeaux University Hospital
Bordeaux, France
2
Dijon University Hospital, Dermatology Department
Dijon, France
3
Dermatology Department, Necker Enfants Malades, APHP
Paris, France
4
Dermatology Department, Saint Louis Hospital, APHP
Paris, France